Radiation Therapy and HL
The use of radiation therapy (RT) has been shown to improve 10-year survival rates in patients with stage I-II Hodgkin’s lymphoma (HL). However, the use of RT in this patient population declined from 56% to 41% between 1998 and 2011.
EU Approves Idelalisib
Idelalisib has been approved by the European Union for the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). Idelalisib, an oral therapy, is an inhibitor of P13K delta, a protein that is overexpressed in many B-cell malignancies.
Improved Survival in Europe
Findings from a retrospective observational study that included patients diagnosed with haematological malignancies from 20 European countries showed that survival increased for most haematological malignancies.
Idelalisib and CLL
A phase III trial examining the use of idelalisib in patients with chronic lymphocytic leukaemia (CLL) will be stopped early as an interim analysis demonstrated significant improvement in progression-free survival, the primary end point.